Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01866254 | Use of Intrathecal Hydromorphone in Elective Cesarean Deliveries | EARLY_PHASE1 | COMPLETED | 45 | — | — | May 1, 2013 | Oct 22, 2018 | Jan 3, 2019 | 1 | United States |
Pain scores to be measured using the verbal response scale (VRS). The VRS pain score is measured on a scale of 0-10 with 0 representing absolutely no pain and 10 representing worst pain imaginable
| Arm | Type | Description |
|---|---|---|
| Hydromorphone | EXPERIMENTAL | 100 mg, intrathecal administration |
| Morphine | ACTIVE_COMPARATOR | 200 mg, intrathecal administration |
| Name | Type | Description |
|---|---|---|
| Hydromorphone | DRUG | Injection of 100 mcg hydromorphone into the intrathecal space |
| Morphine | DRUG | Injection of 200 mcg of intrathecal morphine |
Inclusion Criteria: * Scheduled for elective Cesarean sections under spinal anesthesia or combined spinal anesthesia * ASA status of I-III * BMI \< 40 * Able to understand and sign informed consent Exclusion Criteria: * Severe pre-eclampsia * Conversion to general anesthetic * History of chronic ...